

Lori G. Cohen Tel 678.553.2385 Fax 678.553.2386 cohenl@gtlaw.com

May 28, 2019

VIA CM/ECF AND ELECTRONIC MAIL

The Honorable Joel Schneider United States Magistrate Judge District of New Jersey Mitchell H. Cohen Building & U.S. Courthouse 4th & Cooper Streets Camden, NJ 08101 856-757-5446 856-757-5355 (fax)

> Re: In re Valsartan Products Liability Litigation, U.S. District Court for the District of New Jersey; Case No. 1:19-md-02875-RBK-JS

Dear Judge Schneider:

Enclosed is the current redlined draft of the proposed Confidentiality and Protective Order prepared by the parties. Following several meet and confers, the parties have made significant progress and only a few disputed areas remain for the Court's resolution. Plaintiffs' proposed edits that Defendants have rejected are indicated on the draft in blue line. The parties have flagged paragraphs 21 and 31 with comments for further discussion, as well.

Major areas of disagreement are addressed in the joint agenda submitted on May 24, 2019. (Doc. 107). The parties are prepared to address each of these items further, and look forward to discussing these issues with the Court during the May 29, 2019, in-person Case Management Conference.

Respectfully,

/s Lori G. Cohen

Lori G. Cohen, Esq. Attorney for Teva Pharmaceuticals USA, Inc. and Teva Pharmaceutical Industries Ltd.

Enclosures

The Honorable Joel Schneider May 28, 2019 Page 2

cc: Victoria Lockard, Esq. (via email)

Brian Rubenstein, Esq. (via email)

Adam Slater, Esq. (via email, for distribution to Plaintiffs' Counsel)

Daniel A. Nigh (via email)

Seth A. Goldberg, Esq. (via email, for distribution to Defendants' Counsel)

Richard Smith, Esq. (via email) Clem C. Trischler, Esq. (via email)